These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38457483)

  • 1. DFT and molecular simulation validation of the binding activity of PDEδ inhibitors for repression of oncogenic k-Ras.
    Majrashi TA; Sabt A; Almahli H; El Hassab MA; Noamaan MA; Elkaeed EB; Hamissa MF; Maslamani AN; Shaldam MA; Eldehna WM
    PLoS One; 2024; 19(3):e0300035. PubMed ID: 38457483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring binding modes of the selected inhibitors to phosphodiesterase delta by all-atom molecular dynamics simulations and free energy calculations.
    Zhong H; Zhang YJ; Shan XB
    J Biomol Struct Dyn; 2019 Jun; 37(9):2415-2429. PubMed ID: 30052144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Rahmoune I; Filali H
    Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization.
    Muratcioglu S; Jang H; Gursoy A; Keskin O; Nussinov R
    J Phys Chem B; 2017 Jun; 121(24):5917-5927. PubMed ID: 28540724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity.
    Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors.
    Salmas RE; Mestanoglu M; Yurtsever M; Noskov SY; Durdagi S
    Biophys J; 2015 Sep; 109(6):1163-8. PubMed ID: 26340817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ.
    Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R
    J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.
    Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H
    Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer.
    Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L
    Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex.
    Bello M; Correa-Basurto J; Vargas-Mejía MÁ
    Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
    Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
    J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells.
    Chen YH; Lv H; Shen N; Wang XM; Tang S; Xiong B; Ding J; Geng MY; Huang M
    Acta Pharmacol Sin; 2020 Feb; 41(2):270-277. PubMed ID: 31316177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.
    Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H
    Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of pyrazolopyridazinones as PDEδ inhibitors.
    Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI
    Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas.
    Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH
    Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-Ras
    Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
    Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
    Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
    Chen L; Zhuang C; Lu J; Jiang Y; Sheng C
    J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    Cheng J; Li Y; Wang X; Dong G; Sheng C
    J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.